TNFSF11 and osteoporosis: At present, anti‐RANKL antibodies used to treat osteoporosis in phase III clinical trials on ClinicalTrails.gov include MW031 (NCT05215977), LY06006 (NCT05060406), QL1206 (NCT04128163), and CMAB807 (NCT03925051).